Clinical trial · Interventional
Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study
NCT02324595CI-TRIAL-00021719MISSIONcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase II multicentric study
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Effects of Chemotherapy | — | UNRESOLVED | — |
| Peritoneal Cavity Cancer | Malignant Peritoneal Neoplasm | ALIAS | 0.90 |
| Stage IV Ovarian Carcinoma | Ovarian Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Laparoscopic interval debulking surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Laparoscopic Interval Debulking Surgery
- description
- Patients affected by advanced epithelial ovarian cancer already submitted to neoadjuvant chemotherapy with evidence of complete/partial response
- interventionNames
- Procedure: Laparoscopic interval debulking surgery
Primary outcomes (1)
- measure
- Operative complication rate
- timeFrame
- 30 days
- description
- Intra- and post-operative complication rate of total laparoscopic/robotic interval debulking surgery
Secondary outcomes (2)
- measure
- Progression Free survival
- timeFrame
- one year
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>18 years, * Advanced ovarian cancer submitted to neoadjuvant chemotherapy, * Clinical or serological complete/partial response (RECIST; GCIG), * PS ≤ 2 (ECOG), * Informed consent Exclusion Criteria: * Borderline and non-epithelial ovarian tumors, * Stable/progressive disease, * ASA 3-4, * Severe cardiopulmonary disease, * BMI \> 40
References
Publications (1)
- DERIVEDGueli Alletti S, Bottoni C, Fanfani F, Gallotta V, Chiantera V, Costantini B, Cosentino F, Ercoli A, Scambia G, Fagotti A. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study. Am J Obstet Gynecol. 2016 Apr;214(4):503.e1-503.e6. doi: 10.1016/j.ajog.2015.10.922. Epub 2015 Oct 31. PMID 26529370